HealthcareFirms.com » Drug Manufacturers – Other

Isis Pharmaceuticals, Inc.

admin — Tue, 02 Mar 2010 18:40:16 +0000

Isis has successfully commercialized the world’s first antisense drug and has 22 drugs in development. Isis’ drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer. Isis’ partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide.

ISTA Pharmaceuticals Inc.

admin — Tue, 02 Mar 2010 18:40:16 +0000

ISTA Pharmaceuticals is the fourth largest branded ophthalmic pharmaceutical business in the U.S. ISTA’s four marketed products plus its product candidates include therapies for inflammation, ocular pain, allergy, glaucoma, and dry eye. The Company is developing a strong product pipeline to fuel future growth and market share, supporting its goal to become the leading niche ophthalmic pharmaceutical company in the U.S.

King Pharmaceuticals Inc.

admin — Tue, 02 Mar 2010 18:40:16 +0000

King is a vertically integrated branded pharmaceutical company. King seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products and technologies that complement the Company

Lannett Co. Inc.

admin — Tue, 02 Mar 2010 18:40:16 +0000

Lannett Company, Inc manufactures and distributes pharmaceutical products sold under generic names, and historically, has sold them under trade or brand names as well. The Company’s general business offices, laboratory, manufacturing, distribution and research and development facilities are located in a 31,000 square foot facility situated on 4.5 acres in northeast Philadelphia, Pennsylvania.

Medicines Co.

admin — Tue, 02 Mar 2010 18:40:16 +0000

The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax(R) (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex(R) (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Company also has two products in late stage development: cangrelor, an investigational antiplatelet agent, and oritavancin, a semi-synthetic lipoglycopeptide antibiotic. The Company’s pipeline also includes a serine protease inhibitor, CU2010, in early-stage development

MiddleBrook Pharmaceuticals, Inc.

admin — Tue, 02 Mar 2010 18:40:16 +0000

MiddleBrook Pharmaceuticals, Inc. is a pharmaceutical company focused on commercializing anti-infective products that fulfill unmet medical needs. MiddleBrook’s proprietary delivery technology–PULSYS–enables the pulsatile delivery, or delivery in rapid bursts, of certain drugs. MiddleBrook’s near-term corporate strategy includes improving dosing regimens and/or reducing frequency of dosing to enhance patient dosing convenience and compliance for antibiotics that have been used and trusted by physicians and patients for decades. MiddleBrook currently markets KEFLEX, the immediate-release brand of cephalexin, and MOXATAG -the first and only FDA-approved once-daily amoxicillin.

NeurogesX, Inc.

admin — Tue, 02 Mar 2010 18:40:16 +0000

NeurogesX, Inc. is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this concept and is now poised to bring its lead product to patients and physicians. In addition, it applies its knowledge and expertise in the development of other novel treatments for pain. The Company’s lead product, Qutenza(R) (capsaicin) 8% patch, is a dermal delivery system containing a prescription strength of capsaicin that is currently approved in the United States and the European Union. NeurogesX expects to launch Qutenza in United States in the first half of 2010 for patients with postherpetic neuralgia (PHN). In Europe, Qutenza will be marketed by Astellas Pharma Europe Ltd., (Astellas), the European subsidiary of Tokyo-based Astellas Pharma Inc. The Company’s second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies. The Company’s early stage product pipeline includes pre-clinical compounds which are prodrugs of acetaminophen and various opioids. The Company has evaluated these compounds in vitro and in vivo.

Novo Nordisk A/S

admin — Tue, 02 Mar 2010 18:40:16 +0000

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries.

Opko Health, Inc.

admin — Tue, 02 Mar 2010 18:40:16 +0000

OPKO is a specialty healthcare company involved in the discovery, development, and commercialization of proprietary pharmaceutical and diagnostic products and vaccines. Initially focused on the treatment and management of ophthalmologic diseases, OPKO has since expanded into other areas of major unmet medical need.

Puramed Bioscience Inc

admin — Tue, 02 Mar 2010 18:40:16 +0000

PuraMed BioScience, Inc. engages in the research, development and marketing of non-prescription medicinal and healthcare products. In addition to its leading product LipiGesic

Santarus Inc.

admin — Tue, 02 Mar 2010 18:40:16 +0000

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists and other physicians. The company’s current commercial efforts are focused on ZEGERID® (omeprazole/sodium bicarbonate), which is indicated for the treatment of certain upper GI diseases and disorders, and on GLUMETZA® (metformin hydrochloride extended release tablets), which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Santarus is also developing two late-stage lower GI product candidates, budesonide MMX® and rifamycin SV MMX®, for the U.S. market. Budesonide MMX is being investigated in two multicenter Phase III clinical trials for the induction of remission of mild or moderate active ulcerative colitis. Santarus expects to begin Phase III clinical testing of rifamycin SV MMX in patients with travelers’ diarrhea in the first half of 2010.

SciClone Pharmaceuticals, Inc.

admin — Tue, 02 Mar 2010 18:40:16 +0000

SciClone Pharmaceuticals is a profit-driven, global specialty pharmaceutical company with a substantial international business and a product portfolio of novel therapies for cancer and infectious diseases. SciClone is focused on continuing international sales growth, a cost-containing clinical development strategy, and overall expense management. ZADAXIN(R) (thymalfasin or thymosin alpha 1) is sold in over 30 countries for the treatment of hepatitis B (HBV) and hepatitis C (HCV), certain cancers and as a vaccine adjuvant. SciClone’s pipeline of drug candidates includes thymalfasin, in clinical studies as an enhancer of H1N1 flu vaccines; thymalfasin for stage IV melanoma, for which SciClone has reached agreement with the FDA on the design of a phase 3 trial; SCV-07 in a phase 2 trial for the delay of onset of severe oral mucositis in patients receiving chemoradiation therapy for the treatment of cancers of the head and neck; and SCV-07 in a phase 2 trial for the treatment of HCV. SciClone has exclusive commercialization and distribution rights to DC Bead(TM) in China, where the product is under regulatory review. The Company also has exclusive commercialization and distribution rights to the anti-nausea drug ondansetron RapidFilm(TM) in China and Vietnam, for which it will seek regulatory approval.

Simcere Pharmaceutical Group.

admin — Tue, 02 Mar 2010 18:40:16 +0000

Simcere Pharmaceutical Group is a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells antibiotics, anti-cancer medication and stroke management medication. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases.

Sucampo Pharmaceuticals, Inc.

admin — Tue, 02 Mar 2010 18:40:16 +0000

Sucampo Pharmaceuticals, Inc., an international biopharmaceutical company based in Bethesda, Maryland, focuses on the development and commercialization of medicines based on prostones. The therapeutic potential of prostones, which are bio-lipids that occur naturally in the human body. Sucampo Pharma America, Inc., markets AMITIZA(R) (lubiprostone) 24 mcg in the U.S. for chronic idiopathic constipation in adults and AMITIZA 8 mcg in the U.S. to treat irritable bowel syndrome with constipation in adult women. Sucampo also is developing the drug for additional gastrointestinal disorders with large potential markets.

Teva Pharmaceutical Industries

admin — Tue, 02 Mar 2010 18:40:16 +0000

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 15 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative pharmaceuticals and active pharmaceutical ingredients. Over 80 percent of Teva’s sales are in North America and Western Europe.

Tianyin Pharmaceutical Co.

admin — Tue, 02 Mar 2010 18:40:16 +0000

Tianyin Pharmaceutical Co., Inc. is a leading manufacturer and supplier engaged in the development, manufacturing, marketing and sale of modernized traditional Chinese medicines and other pharmaceuticals in China. It is headquartered in Chengdu, Sichuan province in China with two state-of-the-art manufacturing facilities and an extensive nationwide sales and distribution network throughout China. It currently manufacturea and markets a comprehensive portfolio of 39 products of which 22 are listed in the highly selective National Medicine Catalog of the National Medical Insurance program. In addition, it has a pipeline of 17 products pending regulatory approvals with a sizable upside market potential for continuous growth.

Unigene Laboratories Inc.

admin — Tue, 02 Mar 2010 18:40:16 +0000

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical(R), Unigene’s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline, worldwide rights for its calcitonin manufacturing technology to Novartis and worldwide rights (except for China) for its oral calcitonin program to Tarsa Therapeutics, Inc. Unigene’s patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin and PTH analogs. Unigene’s patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics.

Valeant Pharmaceuticals International

admin — Tue, 02 Mar 2010 18:40:16 +0000

Valeant Pharmaceuticals International is a multinational specialty pharmaceutical company that develops and markets specialty pharmaceutical, branded generic and OTC products that make a meaningful difference in patients’ lives. It is focused primarily on the neurology and dermatology therapeutic areas in the United States, Canada, and Australia markets, while operating branded generics businesses in Latin America and Europe. Based in Orange County, California, it employs approximately 2,300 people worldwide.

Warner Chilcott plc

admin — Tue, 02 Mar 2010 18:40:16 +0000

Warner Chilcott is a leading specialty pharmaceutical company currently focused on the gastroenterology, women’s healthcare, dermatology and urology segments of the North American and Western European pharmaceuticals markets. The Company is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of its products.

Access Pharmaceuticals Inc.